Chapter PDF
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Anderson CM. Drug profiles. In: Perry MC, Anderson CM, Doll DC et al. (eds) Companion Handbook to the Chemotherapy Sourcebook, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, 2004, pp 419–72
Chauncey TR. Drug resistance mechanisms in acute leukemia. Curr Opin Oncol 2001;13:21–6
Egorin MJ. Overview of recent topics in clinical pharmacology of anticancer agents. Cancer Chemother Pharmacol 1998;42(Suppl):22–30
Fischer DS, Knobf MT, Durivage HJ et al. The Cancer Chemotherapy Handbook. Mosby, Philadelphia, 2003, pp 48–241
Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 2000;60(Suppl 1):1–14
Skeel RT. Antineoplastic drugs and biological response modifiers. Classification, use and toxicity of clinically useful agents. In: Skeel RT (ed) Handbook of Cancer Chemotherapy, 6th edn. Lippincott Williams & Wilkins, Philadelphia, 2003, pp 53–156
http://www.druginfonet.com/ Drug Information, Information on Antineoplastic Agents
http://www.meds.com/DChome.html Information on cytostatics
http://chemfinder.cambridgesoft.com Chemical Data Base
http://www.druginfonet.com/ Drug Information Network
http://chemfinder.cambridgesoft.com/ Chemfinder Database
http://www.meds.com/DChome.html Dose Calculation of Cytostatics
Ginsberg JP, Womer WB. Preventing organ-specific chemotherapy toxicity. Eur J Cancer 2005;41:2690–700
Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474–85
http://www.druginfonet.com/ Drug information
http://www.meds.com/DChome.html Information on Cytostatics
Bailey BJ, Briars GL. Estimating the surface area of the human body. Stat Med 1996;15:1325–32
Baker SD, Verweij J, Rowinsky EK et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002;94:883–8
Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep 1970;54:225–35
Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987;317:1098
Reilly JJ, Workman P. Normalization of anti-cancer drug dosage using body weight and surface area: is it worthwhile? Cancer Chemother Pharmacol 1993;32:411–8
http://www.halls.md/body-surface-area/refs.htm BSA, Formulas and Comments
http://www.halls.md/body-surface-area/bsa.htm BSA Calculation
http://www.ultradrive.com/bsac.htm BSA Calculation
Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 1998;56:1019–38
Donelli MG, Zucchetti M, Munzone E et al. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998;34:33–46
Ibrahim S, Honig P, Huang SM et al. Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives. J Clin Pharmacol 2000;40:31–8
Lichtman SM, Villani G. Chemotherapy in the elderly: pharmacologic considerations. Cancer Control 2000;7:548–56
Marx GM, Blake GM, Galani E et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004;15:291–5
Stevens LA, Coresh J, Greene Tet al. Assessing kidney function – measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473–83
http://www.druginfonet.com/ Drug Information (with specialist information)
http://chemfinder.camsoft.com/ Data Base of Chemical Compounds
http://www.meds.com/DChome.html Information on Cytostatics
http://www.manuelsweb.com/IBW.htm IBW calculator
http://medcal3000.com/CreatinineCl.htm Creatinine Clearance Calculator
http://nephron.com/ GFR calculator
Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol 2004;15:146–50
Giacalone PL, Laffargue F, Benos P. Chemotherapy for breast carcinoma during pregnancy. A French national survey. Cancer 1999;86:2266–72
Loibl S, von Minckwitz G, Gwyn K et al. Breast carcinoma during pregnancy. Cancer 2006; 106:237–46
Partridge AH, Garber JE. Long-term outcomes of children exposed to antineoplastic agents in utero. Semin Oncol 2000;27:712–26
Salooja N, Szydio RM, Socie G et al. Pregnancy outcomes after peripheral blood or marrow transplantation: a retrospective survey. Lancet 2001;358:271–6
Williams SF, Schilsky RL. Antineoplastic drugs administered during pregnancy. Semin Oncol 2000;27:618–22
http://www.cancer.gov/cancertopics/pdq/treatment/breast-cancer-and-pregnancy/ NCI Cancernet
http://www.sogc.org/guidelines/public/111E-CPG-February2002.pdf SOGC Guideline
Trissel LA. Handbook on Injectable Drugs, 14th edn. American Society of Health-System Pharmacists, Bethesda, 2007.
http://www.druginfonet.com/ Drug Information (with specialist information)
http://chemfinder.camsoft.com/ Database of Chemical Compounds
http://rxlist.com Internet Drug Index
http://www.meds.com/DChome.html Information on Cytostatics
ASCO. Criteria for facilities and personnel for the administration of parenteral systemic antineoplastic therapy. J Clin Oncol 2004;22:4613–5
Connor TH, McDiarmid MA. Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin 2006;56:354–65
Trissel LA. Handbook on Injectable Drugs, 14th edn. American Society of Health-System Pharmacists, Betherda, 2007
http://www.druginfonet.com/ Drug Information
http://www.meds.com/DChome.html Information on Cytostatics
Boekhout AH, Beijnen JH, Schellens JHM. Symptoms and treatment in cancer therapy-induced early menopause. Oncologist 2006;11:641–54
Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol 2003;30(suppl 14):3–11
Smith RE. A review of Selective Estrogen Receptor Modulators and National Surgical Adjuvant Breast and Bowel Projects clinical trials. Semin Oncol 2003;30(suppl 16):4–13
Writing Group for the Women’s Health Initiative (WHI) Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321–33
Zlotta AR, Schulman CC. Neoadjuvant and adjuvant hormone therapy for prostate cancer. World J Urol 2000;18:179–82
http://www.prostateinfo.com/ Hormone Therapy in Prostate Cancer
http://www.acor.org/TCRC/tclinks6.html Hormone Therapy in Testicular Tumors
http://www.aace.com/ American Association of Clinical Endocrinologists
http://www.duj.com/Article/Hellstrom2/ Hellstrom2.html Testosterone Replacement Therapy
Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10(18 Pt 2):6342S–6S
Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004;4:314–20
Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11–22
Morcellin S, Rossi CR, Pilati P et al. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth factor Rev 2005;16:35–53
Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8–32
http://www.weizmann.ac.il/cytokine International Cytokine Society
http://www.sciencedirect.com/science/journal/10434666 Cytokines Journal
http://www.elsevier.com/wps/product/cws_home/868 Cytokine Growth Factor Reviews
http://cytokine.medic.kumamoto-u.ac.jp Cytokine Family Database
Baselga J. Monoclonal antibodies directed at growth factor receptors. Ann Oncol 2000;11(suppl 3):187–90
Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. J Clin Oncol 2005;23:3235–42
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011–27
Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341–54
López-Guillermo A, Mercadal S. The clinical use of antibodies in haematological malignancies. Ann Oncol 2007;18 ( Suppl. 9): ix51–7
Plosker G, Figgitt, D. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 2003, 63:803–43
Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeuties. Nat Rev Drug Discov 2007;6:349–355
Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol 2003;30:424–33
http://www.oncolink.upenn.edu Oncolink Information
http://www.cancer.org/ American Cancer Society
http://www.nci.nih.gov/ National Cancer Institute, Bethesda, USA
http://www.fda.gov/cber/ FDA, Center for Biologics Evaluation and Research
http://www.gallartinternet.com/mai Monoclonal Antibody Index
http://www.cancerbackup.org.uk/treatments/ biologicaltherapies/monoclonalantibodies Cancer Backup UK
http://en.wikipedia.org/wiki/ monoclonal_antibodies Wikipedia, Monoclonal Antibodies
Bells HS, Ryan KM. Intracellular signalling and cancer: complex pathways lead to multiple targets. Eur J Cancer 2005;41:206–15
Benson C, Kaye S, Workman P et al. Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br J Cancer 2005;92:7–12
Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640–53
Ghobrial IM, Witzig TE, Adjej AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005;55:178–94
Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. J Clin Oncol 2005;23:3235–42
Lancet JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 2003;102:2880–9
Nencioni A, Grünebach F, Patrone F et al. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007;21:20–6
Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505–18
Sabatini DM. mTOR and cancer. Nat Rev Cancer 2006;6:729–34
http://cis.nci.nih.gov/fact/7_49.htm National Cancer Institute
http://www.nature.com/nrc/focus/targetedtherapies Nature Reviews Cancer
http://www.oncolink.com/treatment/treatment.cfm?c=12 Oncolink “Targeted Therapies”
http://www.fda.gov/cder/drug/infopage/gleevec FDA, Glivec Information
Dixon JR. The International Conference on Harmonization Good Clinical Practice Guideline. Qual Assur 1998;6:65–74
EEC note for guidance: good clinical practice for trials on medicinal products in the European Community. CPMP Party on Efficacy of Medicinal Products. Pharmacol Toxicol 1990;67:361–72
Gajic A, Herrmann R, Salzberg M. The international quality requirements for the conduct of clinical studies and the challenges for study centers to implement them. Ann Oncol 2004;15:1305–9
Idanpaan-Heikkila JE. WHO guidelines for good clinical practice (GCP) for trials on pharmaceutical products: responsibilities of the investigator. Ann Med 1994;26:89–94
World Medical Association. Helsinki Declaration, 1975. In: Beauchamp TL, Walters LW (eds) Contemporary Issues in Bioethics, 2nd edn. Wadsworth, Belmont, CA, 1982
http://eudract.emea.europa.eu/ European Clinical Trials Database
http://www.clinicaltrials.gov US Clinical Trials Database
http://www.controlled-trials.com/ Study Register
http://www.centerwatch.com Clinical Trials Listing Service
http://www.emea.europa.eu/ EMEA, European Agency for Evaluation of Medicinal Products
http://www.fda.gov/ FDA, Food and Drug Administration, USA
http://www.ich.org ICH, International Conf. Harmonization
Dervieux T, Meshkin B, Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res 2005;31:90–105
Desai AA, Innocenti F, Ratain MJ. Pharmacogenomics: roads to anticancer therapeutics nirvana? Oncogene 2003;22:6621–8
Lee W, Lockhart AC, Kim RM et al. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 2005;10:104–11
Loni L, De Braud F, Zinzani PL et al. Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin’s lymphoma. Leuk Lymphoma 2003;44(suppl 3):S115–22
Marsh S. Pharmacogenomics. Ann Oncol 2007;18(suppl 9):ix24–8
Stam RW, den Boer ML, Meijerink JP et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003;101:1270–6
Tan BR, McLeod HL. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Semin Oncol 2005;32:113–9
Weinshilboum R, Wand L. Pharmacogenomics: from bench to bedside. Nat Rev Drug Discovery 2004;3:739–48
http:// www.nature.com/tpj/index.html Pharmacogenomics Journal
http://www.ncbi.nlm.nih.gov/About/primer/pharm.html Pharmacogenomics Primer
http://www.pharmgkb.org Pharmacogenetics Database
http://www.nigms.nih.gov/Initiatives/PGRN Pharmacogenetics Research Network
http://snp.cshl.org SNP Consortium
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Berger, D. et al. (2008). Pharmacology and Pharmacotherapy. In: Berger, D., Engelhardt, M., Henß, H., Mertelsmann, R. (eds) Concise Manual of Hematology and Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-73277-8_3
Download citation
DOI: https://doi.org/10.1007/978-3-540-73277-8_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-73276-1
Online ISBN: 978-3-540-73277-8
eBook Packages: MedicineMedicine (R0)